Domo signs strategic collaboration agreement with AWS for AI solutions
Immix Biopharma , Inc. (NASDAQ:IMMX) CEO and Chairman Ilya M. Rachman reported purchasing 2,178 shares of common stock on June 18, 2025. The shares were bought at a volume-weighted average price of $2.295, for a total transaction value of $4998. The purchase comes as the stock shows strong momentum, with InvestingPro data showing returns of over 24% in the past year. With analysts setting a $7 price target and the company maintaining a healthy balance sheet with more cash than debt, this insider purchase draws attention.
Following the transaction, Rachman directly owns 1,138,437 shares of Immix Biopharma, Inc., representing a significant stake in the $66.57 million market cap company. Want deeper insights into insider trading patterns and 8 additional key metrics? Check out InvestingPro for comprehensive analysis.
In other recent news, Immix Biopharma, Inc. has reported encouraging interim results from its Phase 1/2 NEXICART-2 clinical trial for NXC-201, a therapy targeting AL Amyloidosis. The trial demonstrated a 70% complete response rate, with no relapses or significant safety concerns to date. Additionally, Immix Biopharma plans to submit a Biologics License Application for FDA approval based on these findings. The company’s NEXICART-2 trial is progressing ahead of schedule, with 14 U.S. sites now actively enrolling patients, marking a significant increase from previous updates. Immix Biopharma has also entered into an At The Market Offering Agreement with Citizens JMP Securities, LLC, allowing the company to sell shares of its common stock at its discretion. Analysts from H.C. Wainwright have reaffirmed their Buy rating for Immix Biopharma stock, following the presentation of trial results at the annual ASCO meeting. The promising trial outcomes have been highlighted as a basis for maintaining a positive outlook on the company’s stock. Immix Biopharma’s NXC-201 has received Regenerative Medicine Advanced Therapy designation and Orphan Drug Designation from the FDA and EMA, respectively, due to its potential impact on treating AL Amyloidosis.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.